Oscar Health's Revenue Growth and Market Share Surge
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: Fool
Oscar Health Inc. saw its stock rise by 5.04% as it crossed above the 5-day SMA, reflecting positive investor sentiment. The company reported approximately $11.7 billion in revenue for FY 2025, a 27.5% increase, despite a net loss of about $443.2 million, highlighting both challenges and opportunities in a rapidly growing market. With a significant increase in paying members to 3.2 million, Oscar Health is well-positioned for future growth, especially as it guides for $19 billion in revenue for 2026, attracting interest from long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OSCR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OSCR
Wall Street analysts forecast OSCR stock price to fall
8 Analyst Rating
1 Buy
4 Hold
3 Sell
Hold
Current: 28.270
Low
11.00
Averages
15.75
High
25.00
Current: 28.270
Low
11.00
Averages
15.75
High
25.00
About OSCR
Oscar Health, Inc. is a healthcare technology company built around a full stack technology platform. The Company's offerings include its insurance business and +Oscar Platform. Its health plans are offered in the individual market. The individual market primarily consists of policies purchased by individuals and families through health insurance marketplaces, established by the ACA and operated by the federal government, as well as other marketplaces operated by individual states. Individuals and families may also purchase policies in the individual market off-exchange. Employees whose employers have chosen to offer an Individual Coverage Health Reimbursement Arrangement (ICHRA) are also able to purchase its health plans. It offers health plans in the individual market under the five metal plan categories defined by the ACA: Catastrophic, Bronze, Silver, Gold, and Platinum. Through the +Oscar platform, the Company deploys its technology to help others throughout the healthcare system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oscar Health: Disruptor in the Health Insurance Market
- Massive Market Potential: The U.S. healthcare industry spends trillions annually, with growth expected to outpace inflation due to an aging population, presenting significant opportunities for innovative companies like Oscar Health.
- Customer Base Expansion: Oscar Health has grown its customer count to 3.2 million over the past few years, establishing itself as a major player in the ACA marketplace, demonstrating its ability to stand out among traditional insurers with substantial growth potential ahead.
- Record Revenue Guidance: Oscar Health anticipates reaching $19 billion in revenue and $450 million in operating income by 2026, both record figures for the company, indicating its success in leveraging network effects and customer growth.
- Significant Profit Potential: If Oscar Health doubles its customer base to 6.5 million over the next five years, its 2026 premium revenue could reach $50 billion, with a 5% operating margin translating to $2.5 billion in annual operating income, highlighting the investment value of its stock.
See More
Oscar Health's Massive Profit Potential by 2026
- Market Share Growth: Oscar Health has reached 3.2 million customers this year, establishing itself as a major player in the ACA marketplace, indicating a competitive edge over traditional health insurers and expected continued market share expansion.
- Revenue Guidance Innovation: The company anticipates reaching $19 billion in revenue and $450 million in operating income by 2026, both record highs, indicating a significant improvement in profitability within the health insurance sector.
- Enhanced Customer Experience: By offering free telehealth services and dedicated online customer support, Oscar Health has achieved customer satisfaction levels significantly higher than traditional insurers, which is expected to attract new clients and enhance customer loyalty.
- Long-Term Growth Potential: If the customer base doubles to 6.5 million over the next five years, premium revenue could reach $50 billion by 2026, potentially generating $2.5 billion in annual operating income at a 5% margin, highlighting the investment value of its stock.
See More
Applied Materials Opens $500M Singapore Campus, Hits 52-Week High
- Manufacturing Expansion: Applied Materials opened its $500 million Tampines Campus in Singapore, leading its stock to reach a 52-week high of $534.44 on Wednesday, with the new facility more than doubling cleanroom space and helping semiconductor manufacturers meet the growing demand from AI-related technologies, thereby enhancing the company's future growth potential.
- Telecom Technology Milestone: AmpliTech shares climbed to a five-year high of $8.29 after successfully participating in the O-RAN ALLIANCE Global PlugFest, where its advanced radio technology demonstrated interoperability with major telecommunications operators' equipment, marking a significant step toward broader commercial adoption of its 5G infrastructure products and strengthening its position within the Open RAN ecosystem.
- Analyst Rating Upgrade: Oscar Health received support from Barclays analyst Andrew Mok, who upgraded the stock from 'Equal Weight' to 'Overweight' and raised the price target from $30 to $35, noting that Oscar provides investors with a direct way to benefit from growth in the Affordable Care Act insurance market, with greater gains expected if demand for ACA plans continues to rise.
- Strong Market Performance: Despite a broader market pause, shares of Applied Materials, AmpliTech, and Oscar Health all reached new 52-week highs on Wednesday, with AMAT and OSCR stocks surging 93% year-to-date, while AMPG stock jumped over 154%, reflecting strong investor confidence in the future growth of these companies.
See More
Amazon's Logistics Expansion Hits Freight Stocks Hard
- Freight Stocks Decline: Amazon's announcement to open its less-than-truckload shipping services to external companies led to a 5% drop in FedEx Freight and Old Dominion Freight Line, and a 4% decline in XPO, indicating a significant threat to industry incumbents and potential market share erosion.
- Super Micro Stock Plunge: Super Micro Computer's plan to raise $7 billion through equity and equity-linked securities to cover hardware component costs resulted in an 18% stock drop, reflecting market concerns over its financing strategy and potential long-term implications for growth.
- Energy Stocks Rally: Devon Energy's stock surged over 6% after Evercore ISI upgraded its rating to outperform, following a better-than-expected mid-month update post the $58 billion acquisition of Coterra Energy, showcasing strong performance in the oil and gas sector.
- Restaurant Stocks Surge: Cracker Barrel's stock soared 24% after raising its full-year revenue and adjusted EBITDA guidance, reporting fiscal Q3 earnings of $0.29 per share on $797.4 million in revenue, exceeding analyst expectations and indicating robust business recovery.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Oscar Health: Disruptor in the Health Insurance Market
- Massive Market Potential: The U.S. healthcare industry spends trillions annually, with growth expected to outpace inflation due to an aging population, presenting significant opportunities for innovative companies like Oscar Health.
- Customer Base Expansion: Oscar Health has grown its customer count to 3.2 million over the past few years, establishing itself as a major player in the ACA marketplace, demonstrating its ability to stand out among traditional insurers with substantial growth potential ahead.
- Record Revenue Guidance: Oscar Health anticipates reaching $19 billion in revenue and $450 million in operating income by 2026, both record figures for the company, indicating its success in leveraging network effects and customer growth.
- Significant Profit Potential: If Oscar Health doubles its customer base to 6.5 million over the next five years, its 2026 premium revenue could reach $50 billion, with a 5% operating margin translating to $2.5 billion in annual operating income, highlighting the investment value of its stock.
See More
Oscar Health's Massive Profit Potential by 2026
- Market Share Growth: Oscar Health has reached 3.2 million customers this year, establishing itself as a major player in the ACA marketplace, indicating a competitive edge over traditional health insurers and expected continued market share expansion.
- Revenue Guidance Innovation: The company anticipates reaching $19 billion in revenue and $450 million in operating income by 2026, both record highs, indicating a significant improvement in profitability within the health insurance sector.
- Enhanced Customer Experience: By offering free telehealth services and dedicated online customer support, Oscar Health has achieved customer satisfaction levels significantly higher than traditional insurers, which is expected to attract new clients and enhance customer loyalty.
- Long-Term Growth Potential: If the customer base doubles to 6.5 million over the next five years, premium revenue could reach $50 billion by 2026, potentially generating $2.5 billion in annual operating income at a 5% margin, highlighting the investment value of its stock.
See More
Applied Materials Opens $500M Singapore Campus, Hits 52-Week High
- Manufacturing Expansion: Applied Materials opened its $500 million Tampines Campus in Singapore, leading its stock to reach a 52-week high of $534.44 on Wednesday, with the new facility more than doubling cleanroom space and helping semiconductor manufacturers meet the growing demand from AI-related technologies, thereby enhancing the company's future growth potential.
- Telecom Technology Milestone: AmpliTech shares climbed to a five-year high of $8.29 after successfully participating in the O-RAN ALLIANCE Global PlugFest, where its advanced radio technology demonstrated interoperability with major telecommunications operators' equipment, marking a significant step toward broader commercial adoption of its 5G infrastructure products and strengthening its position within the Open RAN ecosystem.
- Analyst Rating Upgrade: Oscar Health received support from Barclays analyst Andrew Mok, who upgraded the stock from 'Equal Weight' to 'Overweight' and raised the price target from $30 to $35, noting that Oscar provides investors with a direct way to benefit from growth in the Affordable Care Act insurance market, with greater gains expected if demand for ACA plans continues to rise.
- Strong Market Performance: Despite a broader market pause, shares of Applied Materials, AmpliTech, and Oscar Health all reached new 52-week highs on Wednesday, with AMAT and OSCR stocks surging 93% year-to-date, while AMPG stock jumped over 154%, reflecting strong investor confidence in the future growth of these companies.
See More
Amazon's Logistics Expansion Hits Freight Stocks Hard
- Freight Stocks Decline: Amazon's announcement to open its less-than-truckload shipping services to external companies led to a 5% drop in FedEx Freight and Old Dominion Freight Line, and a 4% decline in XPO, indicating a significant threat to industry incumbents and potential market share erosion.
- Super Micro Stock Plunge: Super Micro Computer's plan to raise $7 billion through equity and equity-linked securities to cover hardware component costs resulted in an 18% stock drop, reflecting market concerns over its financing strategy and potential long-term implications for growth.
- Energy Stocks Rally: Devon Energy's stock surged over 6% after Evercore ISI upgraded its rating to outperform, following a better-than-expected mid-month update post the $58 billion acquisition of Coterra Energy, showcasing strong performance in the oil and gas sector.
- Restaurant Stocks Surge: Cracker Barrel's stock soared 24% after raising its full-year revenue and adjusted EBITDA guidance, reporting fiscal Q3 earnings of $0.29 per share on $797.4 million in revenue, exceeding analyst expectations and indicating robust business recovery.
See More
Latest Wall Street Ratings Overview
- Tesla's Self-Driving Tech: Piper Sandler reiterates Tesla as overweight, highlighting progress in its full self-driving software despite ongoing market skepticism, reflecting competitive pressures in the autonomous driving sector.
- Hyliion Stock Rating: Needham initiates coverage of Hyliion Holdings with a Buy rating and a $9 target, indicating strong performance in power solutions and showcasing the company's market potential and growth momentum.
- Healthcare Market Opportunity: Barclays upgrades Oscar Health from equal weight to overweight, believing the company's single-line exposure to the Individual ACA market provides direct leverage for potential multi-year re-rating, signaling recovery in margins.
- Nvidia Stock Attractiveness: Rosenblatt reiterates Nvidia as a Buy, emphasizing its leadership in AI computing and strong growth visibility, with shares currently trading at a ~35% discount to peers, indicating significant investment value.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
